Why the study?
Does sulfinpyrazone or aspirin/dipyridamole improve platelet survival time and beta-thromboglobulin levels in patients with angiographically documented coronary artery disease?
Does sulfinpyrazone or aspirin/dipyridamole improve platelet survival time and beta-thromboglobulin levels in patients with angiographically documented coronary artery disease?
In patients with CAD, treatment with sulfinpyrazone or aspirin/dipyridamole had no measurable effect on platelet survival time or beta-thromboglobulin levels compared to placebo.
Answers are grounded in this paper and cite their sources.
No effect on platelet markers in CAD; challenges presumed mechanism and utility of these agents.
This study was designed to clarify discrepancies in the literature concerning platelet survival time and beta-thromboglobulin (beta TG) levels in patients with coronary artery disease (CAD) and the effect of platelet-suppressant drugs on these tests. Platelet survival time and plasma beta TG levels were determined in 48 patients with angiographically documented CAD. The effect of sulfinpyrazone or aspirin/dipyridamole on these measurements was investigated in a double-blind, crossover trial that included a placebo phase. In patients with CAD, the mean plasma beta TG concentration was significantly elevated, but the mean platelet survival time was not significantly different from that in controls. Treatment with sulfinpyrazone or aspirin/dipyridamole did not produce changes in platelet survival time or plasma beta TG concentration that were significantly different from the values during the placebo phase. This study demonstrates that compared with the spontaneous variation in platelet survival time or beta TG concentration, there was no measureable effect of sulfinpyrazone or aspirin/dipyridamole on the results of the tests.
No takes yet. Share an insight, caveat, or question.
Boer et al. (1983) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: